drugset / Trial / NCT00976508
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
Timeline
- Start
- 2009-11
- Primary completion
- 2011-09
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Figitumumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Pegvisomant | Protein / enzyme biologic | 10 mg | Subcutaneous |
| Subject | Pegvisomant | Protein / enzyme biologic | 20 mg | Subcutaneous |
| Subject | Pegvisomant | Protein / enzyme biologic | 30 mg | Subcutaneous |